Humacyte, Inc. 8-K

What Happened
Humacyte, Inc. (HUMA) held its 2026 Annual Meeting of Stockholders on June 9, 2026. Following the recommendation of its board of directors, stockholders approved an amendment to the company’s Second Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 350,000,000 to 550,000,000. The Certificate of Amendment became effective upon filing with the Delaware Secretary of State on June 9, 2026; the amendment is filed as Exhibit 3.1 to the company’s 8-K.

Key Details

• Annual Meeting date: June 9, 2026; amendment approved by stockholders.
• Authorized common shares increased from 350,000,000 to 550,000,000 (an increase of 200,000,000 shares).
• Amendment effective upon filing with the Delaware Secretary of State on June 9, 2026.
• Certificate of Amendment included as Exhibit 3.1 to the 8-K filing.

Why It Matters
An increase in authorized common shares does not change outstanding shares or ownership percentages by itself, but it gives the company legal capacity to issue up to 200 million additional shares in the future. That flexibility can be used for capital raises, stock-based compensation, acquisitions, or other corporate purposes; any actual issuance would be disclosed in future SEC filings and could dilute existing shareholders. Investors should monitor subsequent filings (e.g., registration statements, 8‑Ks, and Forms 4/S‑1) for any planned issuances or offerings.